Premium
Cyclooxygenase‐2 expression in oral tongue squamous cell carcinoma
Author(s) -
Ryott Michael,
Marklund Linda,
Wangsa Darawalee,
Elmberger Göran,
MunckWikland Eva
Publication year - 2011
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.2010.00992.x
Subject(s) - cyclooxygenase , immunostaining , immunohistochemistry , medicine , pathology , malignancy , stage (stratigraphy) , cancer , carcinoma , biology , enzyme , paleontology , biochemistry
J Oral Pathol Med (2010) 40 : 385–389 Background: Cyclooxygenase‐2 expression is associated with unfavorable outcome in various cancers, and evidence is accumulating that carcinogenesis possibly evolves from intracellular changes in response to induction of this enzyme. Today selective cyclooxygenase‐2 inhibitors are being studied and used as complement in cancer treatment. This study examined the prognostic value of cyclooxygenase‐2 expression in oral tongue squamous cell carcinoma (OTSCC). Methods: Expression of cyclooxygenase‐2 was determined in biopsies from 76 stage matched patients with OTSCC by immunohistochemistry between January 2000 and December 2004 in Stockholm, Sweden. Additionally, twelve samples taken after pre‐operative radiotherapy were investigated. Results: All OTSCC specimen expressed cyclooxygenase‐2 by immunostaining. The cyclooxygenase‐2 staining intensity increased significantly with more advanced stage ( P = 0.020). Fifty percent of the surgical specimen showed a decrease in immunostaining post‐radiation ( P = 0.031). No association was found with survival. Conclusion: Cyclooxygenase‐2 expression has limited prognostic value in OTSCC.